Literature DB >> 7051912

Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones.

G S Tint, G Salen, A Colalillo, D Graber, D Verga, J Speck, S Shefer.   

Abstract

Ursodeoxycholic acid, 250 to 300, 500 to 600, or 900 to 1000 mg/d, was given orally for 6 to 38 months to 53 patients with cholesterol gallstones and functioning gallbladders. Forty-two patients had greater than 50% reduction in gallstone volume, number, or both, without apparent dose dependence and 27 of these patients had complete gallstone dissolution. Results of laboratory studies including liver function tests were not affected adversely and biliary lithocholic acid concentration did not increase during therapy. Most biliary symptoms seemed to disappear within 3 months and no patient developed diarrhea. Large diameter and increased number of gallstones were found to hinder dissolution. The percentage of biliary ursodeoxycholic acid increased with increasing dose and reached a maximum of 50% to 60% of total bile acids at a dose of about 10 to 12 mg/kg body weight. d. Biliary lithogenic index was reduced significantly during treatment with ursodeoxycholic acid, 500 to 600 and 900 to 1000 mg/d. Thus, ursodeoxycholic acid appears to be a safe and effective alternative to surgery in selected patients with gallstones.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7051912     DOI: 10.7326/0003-4819-97-3-351

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  32 in total

1.  Cost-effectiveness of ursodiol: the creature from the black box.

Authors:  A K Diehl
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

Review 2.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

Review 3.  Use of ursodeoxycholic acid in patients with liver disease.

Authors:  Paul Angulo
Journal:  Curr Gastroenterol Rep       Date:  2002-02

4.  Extension of selection criteria for extracorporeal shock wave lithotripsy for gall stones.

Authors:  A Darzi; J R Monson; C O'Morain; W A Tanner; F B Keane
Journal:  BMJ       Date:  1989-07-29

5.  Medical management of gallstones: a cost-effectiveness analysis.

Authors:  M C Weinstein; C M Coley; J M Richter
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

6.  Is routine cholecystectomy indicated for asymptomatic cholelithiasis in patients undergoing gastric bypass?

Authors:  William Fuller; Jason J Rasmussen; Jagannath Ghosh; Mohamed R Ali
Journal:  Obes Surg       Date:  2007-06       Impact factor: 4.129

7.  Usefulness of gallbladder ejection fraction estimation to predict the recurrence of biliary pain in patients with symptomatic gallstones who did not undergo cholecystectomy.

Authors:  Sung Noh Hong; Jong Kyun Lee; Kyu Taek Lee; Jin Seok Heo; Seong Ho Choi; Poong Lyul Rhee; Seung Woon Paik; Byung Chul Yoo; Jong Chul Rhee
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

8.  Hydrophobic bile salt inhibits bacterial adhesion on biliary stent material.

Authors:  J Y Sung; E A Shaffer; K Lam; I Rususka; J W Costerton
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

9.  Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial.

Authors:  Karl Miller; Emanuel Hell; Barbara Lang; Elisabeth Lengauer
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

10.  Bile acids in treatment of ocular disease.

Authors:  Jeffrey H Boatright; John M Nickerson; Anisha G Moring; Machelle T Pardue
Journal:  J Ocul Biol Dis Infor       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.